Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | HTR3A | P46098 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.35 |
| ▸ | CCR4 | P51679 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4418832 | 0.92 | P2RY12 (0.54) | P2RY12RXFP1MEN1KMT2ATP53 | |
| SCHEMBL4415290 | 0.88 | P2RY12 (0.52) | P2RY12RXFP1MEN1KMT2ATP53 | |
| SCHEMBL4413815 | 0.88 | P2RY12 (0.51) | P2RY12RXFP1MEN1KMT2ATP53 | |
| SCHEMBL4412345 | 0.88 | P2RY12 (0.49) | P2RY12RXFP1MEN1KMT2ATP53 | |
| SCHEMBL4425407 | 0.87 | P2RY12 (0.51) | P2RY12RXFP1MEN1KMT2ATP53 | |
| SCHEMBL13635070 | 0.87 | P2RY12 (0.52) | P2RY12RXFP1MEN1KMT2ATP53 | |
| SCHEMBL4412718 | 0.86 | P2RY12 (0.54) | P2RY12RXFP1MEN1KMT2ATP53 | |
| SCHEMBL13635114 | 0.86 | P2RY12 (0.66) | P2RY12RXFP1MEN1KMT2ATP53 | |
| SCHEMBL4415315 | 0.86 | P2RY12 (0.52) | P2RY12RXFP1MEN1KMT2ATP53 | |
| SCHEMBL4415214 | 0.85 | P2RY12 (0.49) | P2RY12RXFP1MEN1KMT2ATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1668002-B1 | 2,4-DIOXO-3-QUINAZOLINYLARYL SULFONYLUREAS | PORTOLA PHARM INC (US) | 2009-11-11 | — | — | EP | disclosed |
| EP-1668002-B1 | 2,4-DIOXO-3-QUINAZOLINYLARYL SULFONYLUREAS | PORTOLA PHARM INC (US) | 2009-11-11 | — | — | EP | disclosed |
| EP-1668002-A4 | 2,4-DIOXO-3-QUINAZOLINYLARYL SULFONYLUREAS | PORTOLA PHARM INC (US) | 2006-12-20 | — | — | EP | disclosed |
| US-7109332-B2 | 2,4-dioxo-3-quinazolinylaryl sulfonylureas | PORTOLA PHARMACEUTICALS, INC. (US) | 2006-09-19 | — | — | US | disclosed |
| EP-1668002-A2 | 2,4-DIOXO-3-QUINAZOLINYLARYL SULFONYLUREAS | Portola Pharmaceuticals, Inc. (US) | 2006-06-14 | — | — | EP | disclosed |
| US-20050107357-A1 | 2,4-dioxo-3-quinazolinylaryl sulfonylureas | PORTOLA PHARMACEUTICALS, INC. (US) | 2005-05-19 | — | — | US | disclosed |
| WO-2005032488-A2 | 2,4-DIOXO-3-QUINAZOLINYLARYL SULFONYLUREAS | PORTOLA PHARMACEUTICALS, INC. (US) | 2005-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107357-A1 | 2,4-dioxo-3-quinazolinylaryl sulfonylureas | PFKP, DPP3, P2RY13 | P2RY12 21/4885RXFP1 2023/4885MEN1 4319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.